Bariatric surgery may provide the key to slowing down disease progression in morbidly obese individuals with chronic kidney disease (CKD), according to data presented at ASN Kidney Week 2019, underpinning the role of weight loss in this setting.
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
The combination of sacubitril and valsartan results in fewer renal events and slows kidney disease progression vs valsartan alone in patients with heart failure (HF) and preserved ejection fraction (HFpEF) in the post-hoc analysis of 5,000 patients from the PARAGON-HF trial.
Excursions of serum potassium levels above the normal range pose an increased risk of death to haemodialysis patients, with the risk increasing progressively according to the number of hyperkalaemia (HK) episodes regardless of the threshold, according to data from the DOPPS study presented at the American Society of Nephrology (ASN) Kidney Week 2019.
Anaemia negatively impacts not only the physical but also the emotional and social health of chronic kidney disease (CKD) patients, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
Anaemia as a complication of chronic kidney disease (CKD) is seen to adversely affect quality of life (QoL), according to the results of a survey involving Chinese patients, which were presented at the recent American Society of Nephrology (ASN) Kidney Week 2019 in Washington, DC, in the US.
Roxadustat, an oral hypoxia–inducible factor prolyl hydroxylase inhibitor (HIF-PHI), provides significantly greater increases in mean haemoglobin (Hb) levels from baseline than epoetin alfa and placebo in dialysis-dependent patients and dialysis-independent patients with chronic kidney disease (CKD), respectively, according to late-breaking results of the ROCKIES and OLYMPUS trials presented at the American Society of Nephrology (ASN) Meeting 2019.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Despite a 90-percent cure rate after first treatment for children with acute lymphoblastic leukaemia (ALL), approximately 10–15 percent of patients with paediatric ALL will experience relapse. [Expert Rev Anticancer Ther 2017;17:725-736] A recent webinar on the current landscape of ALL highlighted the potential of immunotherapy for paediatric patients with relapsed or refractory ALL, thus providing hope for this high-risk patient group.